Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents
Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, Stefanie Gröpper, Anna Jonasova, Norbert Vey, Ghulam J. Mufti, Rena Buckstein, Moshe Mittelman, Uwe Platzbecker, Ofer Shpilberg, Ron Ram, Consuelo Del Cañizo, Norbert Gattermann, Keiya Ozawa, Alberto Risueño, Kyle J. MacBeth, Jianhua Zhong, Francis Séguy, Albert HoenekoppC. L. Beach, Pierre Fenaux
Research output: Contribution to journal › Article › peer-review
187Scopus
citations
Fingerprint
Dive into the research topics of 'Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents'. Together they form a unique fingerprint.